Member access

4-Traders Homepage  >  Shares  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Ranbaxy Laboratories Limited    RANBAXY   INE015A01028

End-of-day quote. End-of-day quote NATIONAL STOCK EXCHANGE OF INDIA - 03/03
731.25 INR   +0.58%
02/10 SUN PHARMA -WE : Uday Baldota
02/03 Sun pharma receives us ftc clearance for ranbaxy acquisition
01/30 RANBAXY LABORAT : FTC clears Sun Pharma's $4B purchase of competitor..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Ranbaxy Resumes Generic Lipitor Production for U.S.

02/22/2013 | 12:05pm US/Eastern

Ranbaxy Laboratories Ltd. (500359.BY) said Friday it has resumed manufacturing generic copies of the cholesterol-lowering drug Lipitor for the U.S. market, following a production suspension late last year after tiny glass particles were found in the product.

Ranbaxy voluntarily recalled about 480,000 bottles of generic Lipitor, also known as atorvastatin calcium, in the U.S. in November, after discovering the glass fragment problem.

An Indian unit of Japan's Daiichi Sankyo Co. (DSNKY, 4568.TO), Ranbaxy said Friday it's working with the U.S. Food and Drug Administration as it implements corrective actions designed to prevent future manufacturing problems.

Ranbaxy has commenced production of the drug substance for its atorvastatin product, as part of the first step toward resuming supplies to the U.S. market, the company said in a statement.

The recall didn't affect Ranbaxy's generic Lipitor product outside the U.S.

In January, Ranbaxy said it completed an investigation of the manufacturing problem that caused the glass particles to turn up in the product. The company previously said it suspected that a faulty tank at a facility in India caused the problem.

Ranbaxy was one of the biggest sellers of generic Lipitor in the U.S. after Pfizer Inc. (>> Pfizer Inc.) lost exclusivity for the branded product in late 2011.

But Ranbaxy's share of the generic Lipitor market has plunged to 2% from about 45% before the recall, according to J.P. Morgan, which cited data from IMS Health. Other generic companies including Mylan Inc. (>> Mylan Inc.) and Apotex Inc. have gained share of the generic Lipitor market.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Mylan Inc., Pfizer Inc.
React to this article
Latest news on RANBAXY LABORATORIES LIMIT
06:39a RANBAXY LABORATORIES : Loses drug pleas in us
02/24 MUKESH AMBANI : Shanghvi shines brighter than Ambani in rich list
02/21 Going by market value, Sun Pharma's Dilip Shanghvi is richest Indian
02/19 SHANGHVI's SHOPPING CART ROLLS BEYOND PHARMA
02/16 Ipca Labs Acquires Krebs Biochemicals
02/13 Sun plans to close ranbaxy deal by mid-feb 2015
02/12 RANBAXY LABORATORIES : Patent Application Titled "Febuxostat Solid Dispersion" P..
02/11 RANBAXY LABORATORIES : Researchers Submit Patent Application, "Taste Masked Disp..
02/10 SUN PHARMACEUTICALS : `we would like to make one plus one more than two'
02/10 SUN PHARMA -WE WOULD LIKE TO MAKE ON : Uday Baldota
Advertisement
Chart
Duration : Period :
Ranbaxy Laboratories Limit Technical Analysis Chart | RANBAXY | INE015A01028 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF